Education and Training
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: 68-Ga RM2
- drug: 68-Ga PSMA11
- device: Investigational software and coils in PET/MR Scan
- procedure: PET/MRI
Eligibility
Inclusion Criteria:
- Known prostate cancer
- Planned HIFU or HDR local therapy
- Able to provide written consent
- Karnofsky performance status of 50 (or Eastern Cooperative Oncology Group (ECOG)
/World Health Organization (WHO) equivalent)
Exclusion Criteria:
- Patients not capable of getting PET study due to weight, claustrophobia, or inability
to lay still for the duration of the exam
- Metallic implants (contraindicated for MRI)
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Brittney Williams
650-736-3688
Not Recruiting